Sunday, 12 November 2017

Sponsored Session
10:00 - 13:00

SS1, Pre-Congress Symposia

Clinical Practice Session
13:30 - 15:00

G1, Introduction to Parkinson Disease

Learning Objectives
- To outline the clinical definition of Parkinson disease
- To describe the signs of Parkinson disease that precede motor manifestations
- To describe the time course of motor signs in Parkinson disease

Chair: Carlos Singer (Miami, FL, United States)

13:30 - 14:00
The Clinical Definition of Parkinson Disease
Speaker: Erik Ch. Wolters (Amsterdam, Netherlands)

14:00 - 14:30
Pre-Motor Manifestations in Parkinson Disease
Speaker: Caroline Tanner (San Francisco, CA, United States)

14:30 - 15:00
Early and Late Motor Manifestations of Parkinson Disease
Speaker: Tanya Simuni (Chicago, IL, United States)

Timeline Parallel Session
13:30 - 15:00

F2, From Mice to Primates: New Animal Models of Movement Disorders

Learning Objectives
- To describe the major animal models in Parkinson disease
- To describe the emerging animal models in progressive supranuclear palsy
- To describe the advances in animal models of dystonia

Chair: Antonio Pisani (Rome, Italy)

13:30 - 14:00
The Most Promising Models in Parkinson’s Disease
Speaker: Antonio Pisani (Rome, Italy)

14:00 - 14:30
Emerging Models in Progressive Supranuclear Palsy
Speaker: Etienne Hirsch (Paris, France)
Progress in Dystonia Animal Models in the Last Decade
Speaker: Mark S. LeDoux (Memphis, United States)

14:30 - 15:00

Pho Hot Topic Session
13:30 - 15:00

C2, Focusing on Genetics and Imaging in Movement Disorders

Learning Objectives
- To explain the status of gene based therapies for movement disorders
- To describe genetic testing in movement disorders
- To discuss the current status of imaging techniques in understanding movement disorder pathology

Chair: Shinsuke Fujioka (Fukuoka, Japan)
Chair: Andreas Puschmann (Lund, Sweden)

13:30 - 14:00
The Promise of Gene Based Technology in Movement Disorders
Speaker: Nobutaka Hattori (Tokyo, Japan)

14:00 - 14:30
The Most Relevant Advances in Genetic Testing in Movement Disorders
Speaker: Hui-Fang Shang (Chengdu, Sichuan, China)

14:30 - 15:00
Imaging Techniques That are Leading the Way in Understanding Movement Disorders
Speaker: Jon Stoessl (Vancouver, Canada)

Point-Counterpoint Interactive Session
13:30 - 15:00

D3, Dementia With Lewy Bodies and Parkinson Disease Dementia: Is It the Same Disease?

Learning Objectives
- To outline the evidence for and against considering dementia with Lewy bodies (DLB) and Parkinson disease dementia (PDD) as the same disease

Chair: Carlo Colosimo (Terni, Italy)

13:30 - 14:00
Dementia With Lewy Bodies and Parkinson Disease Dementia: It is the Same Disease!
Speaker: Joseph Friedman (Rhode Island, United States)

14:00 - 14:30
Dementia With Lewy Bodies and Parkinson Disease Dementia: It is NOT the Same Disease!
Speaker: Francesc Valdeoriola (Barcelona, Spain)

14:30 - 14:45
Debate

14:45 - 15:00
Question and Answer

Oral Poster Session
13:30 - 15:00

OP-1, Oral Poster Presentation - Session I Basic Neuroscience & Other Movement Disorders

Chair: Lorraine Kalia (Toronto, Canada)
Chair: Alberto Espay (Cincinnati, OH, United States)
Botulinum toxin: central or peripheral mechanism of action?
Speaker: Zdravko Lackovic (Zagreb, Croatia)

Reprogramming in inflammatory response to neuronal damage induced by the brain LPS preconditioning: possible implications in rat model of Parkinson’s disease
Speaker: Mojtaba Golpich (Kuala Lumpur, Malaysia)

Clinico-genetic correlation in Indian Spinocerebellar ataxia Type 1 (SCA1) patients
Speaker: Amit Takkar (Delhi, India)

Prevalence of hemochromatosis (HFE) gene mutations in Friedreich’s Ataxia patients and peripheral neuropathy
Speaker: Inder Singh (New Delhi, India)

Movement disorders in patients with Japanese encephalitis: Experience in a tertiary care hospital in North Eastern region of India
Speaker: Amit Ranjan Barua (Guwahati, India)

Voxel-based meta-analysis of gray and white matter volume reductions in spinocerebellar ataxia type 2
Speaker: Qing Han (Chengdu, China)

Non-motor symptoms in patients with autosomal dominant spinocerebellar ataxia
Speaker: Nitish Kamble (Bangalore, India)

Identification of MicroRNAs and their target genes modulating Spinocerebellar Ataxia type-2 (SCA2) pathogenesis
Speaker: Vishnu Swarup (New Delhi, India)

Prevalence of Parkinson’s disease and drug-induced Parkinsonism from National Health Insurance Service Claims Data (NHISCD)
Speaker: Hyeo-Il Ma (Anyang, Korea, Republic of)

Clinical profile of normal pressure hydrocephalous patients with suggested phenotypic variants
Speaker: Mrinal Kumar Acharya (Kolkata, India)

Phenotypic differences in genetically characterized Spinocerebellar Ataxia Type 2(SCA2): a largest case series from India
Speaker: Akhilesh Kumar Sonakar (New Delhi, India)

Clinical features and differential diagnostic criteria of PANDAS syndrome and Sydenham’s chorea
Speaker: Iroda Nasirova (Tashkent, Uzbekistan)

To study the genotype - phenotype correlation of Friedreich’s Ataxia (FRDA) patients in Indian population
Speaker: Istaq Ahmad (Delhi, India)

Meeting the Professor
13:30 - 15:00
Meet the Professor Lounge (Exhibition)

J1, Meet the Professor 1
Professor: Joachim Krauss (Hannover, Germany)
B1, Can Biomarkers Lead Us to Understanding and Conquering Parkinson Disease?

Learning Objectives
- To describe the general features of biomarkers in Parkinson disease
- To understand the use of biomarkers to aid in early diagnosis of Parkinson disease
- To review the status of biomarkers in cognition and behavior in Parkinson disease

Chair: Erik Ch. Wolters (Amsterdam, Netherlands)
Chair: Daniel Truong (Fountain Valley, CA, United States)

15:30 - 16:00
Unlocking the Mystery of Biomarkers: A Brief Introduction, Its Challenges and Opportunities in Parkinson Disease
Speaker: Alice Chen-Plotkin (Philadelphia, PA, United States)

16:00 - 16:30
How Biomarkers Are Uncovering Rate of Parkinson's Disease Progression
Speaker: Jennifer Yarden (Haifa, Israel)

16:30 - 17:00
The Emerging Role of Biomarkers in Cognition and Behavior in Parkinson Disease
Speaker: Lorraine Kalia (Toronto, Canada)

OC, Opening Ceremony & Melvin Yahr Lectures

17:30 - 17:35
Traditional Vietnamese drum performance
Speaker: Daniel Truong (Fountain Valley, CA, United States)

17:35 - 17:45
Welcome
Speaker: Daniel Truong (Fountain Valley, CA, United States)

17:45 - 18:15
Melvin Yahr lecture I: The 200 Year Journey of Parkinson Disease: Reflecting on the Past and Looking Towards the Future
Speaker: Stanley Fahn (New York, NY, United States)

18:15 - 18:45
Melvin Yahr lecture II: Deep Brain Stimulation Surgery in Movement Disorders: Lessons From The Last 3 Decades
Speaker: Elena Moro (Grenoble, France)
Speaker: Joachim Krauss (Hannover, Germany)

18:45 - 19:00
Performance of the Vietnamese dance group

19:00 - 19:05
Closing
Speaker: Daniel Truong (Fountain Valley, CA, United States)

19:05 - 19:15
Performance of the Vietnamese dance group
Monday, 13 November 2017

Clinical Practice Session
08:30 - 10:00
Room "Pollux 1"

G2, Autonomic Dysfunction in Parkinson Disease

Learning Objectives
- To characterize cardiovascular dysfunction in Parkinson disease
- To characterize gastrointestinal complications in Parkinson disease
- To characterize urogenital issues in Parkinson disease

Chair: Ronald Pfeiffer (Portland, OR, United States)
Chair: Hung Truong Nguyen (Hanoi, Viet Nam)

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30 - 09:00</td>
<td>Cardiovascular Dysfunction in Parkinson Disease</td>
<td>Horaico Kaufmann (New York, NY, United States)</td>
</tr>
<tr>
<td>09:00 - 09:30</td>
<td>Gastrointestinal Complications in Parkinson Disease</td>
<td>Ailton Melo (Salvador, Brazil)</td>
</tr>
<tr>
<td>09:30 - 10:00</td>
<td>Urogenital Issues in Parkinson Disease</td>
<td>Karen Frei (Loma Linda, CA, United States)</td>
</tr>
</tbody>
</table>

Clinical Practice Session
08:30 - 10:00
Room "Pollux 2"

G3, Neuropathology and Behavioral Dysfunction in Parkinson Disease

Learning Objectives
- To describe the neuropathology of Parkinson disease
- To characterize symptoms of fatigue, apathy, and depression in Parkinson disease
- To outline the similarities and differences of Parkinson disease dementia (PDD) and dementia with Lewy bodies

Chair: Stuart Isaacson (Boca Raton, FL, United States)

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30 - 09:00</td>
<td>Neuropathology of Parkinson Disease</td>
<td>Dennis Dickson (Jacksonville, FL, United States)</td>
</tr>
<tr>
<td>09:00 - 09:30</td>
<td>Fatigue, Apathy and Depression in Parkinson Disease</td>
<td>Joseph Friedman (Rhode Island, United States)</td>
</tr>
<tr>
<td>09:30 - 10:00</td>
<td>The Overlapping Syndromes of Parkinson Disease Dementia and Dementia With Lewy Bodies</td>
<td>Irena Rektorova (Brno, Czech Republic)</td>
</tr>
</tbody>
</table>

Pho Hot Topic Session
08:30 - 10:00
Room "Castor 1"

C3, Focusing on New Targets for Therapy

Learning Objectives
- To discuss the glucocerebrosidase (GBA) gene and its potential as a therapeutic target
- To discuss glucagon-like peptide -1 and its potential as a therapeutic target
- To discuss alpha synuclein antibodies as therapies

Chair: Tanya Simuni (Chicago, IL, United States)

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30 - 09:00</td>
<td>Spotlight on Glucocerebrosidase</td>
<td>Weidong Le (Dalian, China)</td>
</tr>
</tbody>
</table>
**Spotlight on Glucagon-Like Peptide-1**
Speaker: Shinsuke Fujioka (Fukuoka, Japan) 09:00 - 09:30

**Spotlight on the Alpha Synuclein Antibodies**
Speaker: Lorraine Kalia (Toronto, Canada) 09:30 - 10:00

---

**Point-Counterpoint Interactive Session**
08:30 - 10:00  
Room "Castor 2"

**D2, Is Parkinson Disease a Prion Disease?**

**Learning Objectives**
- To understand the evidence for and against the hypothesis that Parkinson disease is a prion disease

Chair: Francesc Valldeoriola (Barcelona, Spain)

- **Yes - Parkinson Disease is a Prion Disease!**
  Speaker: Wassilios Meissner (Bordeaux, France) 08:30 - 09:00

- **No - Parkinson Disease is NOT a Prion Disease!**
  Speaker: James Surmeier (Chicago, IL, United States) 09:00 - 09:30

- **Debate** 09:30 - 09:45

- **Question and Answer** 09:45 - 10:00

---

**Timeline Parallel Session**
08:30 - 10:00  
Room "Castor 3"

**F8, Treating the Most Challenging Behavioral and Cognitive Issues in Parkinson Disease**

**Learning Objectives**
- To understand the evolution of the treatment of psychosis in Parkinson disease
- To describe the history and treatment of impulse control behavior disorders in Parkinson disease
- To explain the challenges associated with dementia and its treatment in Parkinson disease

Chair: Hui-Fang Shang (Chengdu, Sichuan, China)

- **The Evolution of PD Psychosis Treatment**
  Speaker: Daniel Weintraub (Philadelphia, PA, United States) 08:30 - 09:00

- **The Rise and Fall of Impulse Control Behavior Disorders**
  Speaker: Carlo Colosimo (Terni, Italy) 09:00 - 09:30

- **Facing the Challenges When Dementia Sets In**
  Speaker: Mark Lew (Los Angeles, CA, United States) 09:30 - 10:00

---

**Oral Poster Session**
08:30 - 10:00  
Poster Exhibition

**OP-2, Oral Poster Presentation - Session II Parkinson 1: Etiology/ Epidemiology/ Pathophysiology**

Chair: Antonio Pisani (Rome, Italy)  
Chair: Emanuele Cereda (Pavia, Italy)

- **The findings of dysphagia in patients with Parkinson's disease, using videofluoroscopic study**
  Speaker: Seong Hoon Lim (kyungki-do, Korea, Republic of)
Validity of the 5-item clock-drawing scoring system in screening of dementia in Parkinson's disease patients
Speaker: Chanya Tangkanakul (Pathumthani, Thailand)

Depression and executive functions modulate motor-related brain activity in parkinsonians
Speaker: Jin Yan (Shenzhen, China)

LRRK2 variant is associated with lower risk of essential tremor
Speaker: Shin Hui Ng (Singapore, Singapore)

Prevalence of cerebral and cardiovascular disease in Parkinson's disease patients: A meta-analysis
Speaker: Chien Tai Hong (New Taipei City, Taiwan)

White matter alterations in Parkinson's disease with normal cognition precede grey matter atrophy
Speaker: Ivan Rektor (Brno, Czech Republic)

Epidemiology of Parkinson's disease in Africa: challenges and opportunities
Speaker: Daniel Gams Massi (Dakar, Senegal)

Depression in Parkinson's disease: A case-control study
Speaker: Ming-Hong Chang (Taichung, Taiwan)

Motor-symptom laterality affects acquisition in Parkinson's disease: a cognitive and functional magnetic resonance imaging study
Speaker: Pei Huang (Shanghai, China)

Putaminal dopamine depletion patterns in de novo Parkinson's disease predicts later development of motor complication types
Speaker: Young H. Sohn (Seoul, Korea, Republic of)

Variants in MCCC1/LAMP3 and DGKQ identified through GWAS are not associated with PD in a Malaysian Malay cohort
Speaker: Jia Lun Lim (Kuala Lumpur, Malaysia)

The modifying effect of age on survival in Parkinson's disease: big data analysis
Speaker: Chava Peretz (Tel Aviv, Israel)

Association between serum uric acid levels and disease severity in Parkinson patients
Speaker: Phuong To Thi Bich (Nha Trang City, Viet Nam)

Apathy in drug-naïve patients with Parkinson's disease
Speaker: Hui Liu (Chengdu, China)

Cardinal symptoms of Parkinson's disease cohabit with levodopa-induced dyskinesia
Speaker: Etienne Goubault (Montréal, Canada)

The association of perceived stress and the frequency and severity of non-motor symptoms in Parkinson's disease
Speaker: Melanie Cusso (Southport, Australia)

Plenary Session
10:30 - 12:00

B2, Understanding the Complex Web of Cognitive Dysfunction and Movement Disorders

Learning Objectives
- To identify the scope of cognitive dysfunction in movement disorders
- To describe the tauopathies and the link between aggregated tau protein and cognitive dysfunction
- To describe cognitive dysfunction and movement disorders in adult-onset leukoencephalopathies

Chair: Eng-King Tan (Singapore, Singapore)
Chair: Peter Riederer (Wuerzburg, Germany)
The Spectrum of Mild Cognitive Impairment to Dementia in Parkinson Disease
Speaker: Daniel Weintraub (Philadelphia, PA, United States)

Untangling the Tauopathies
Speaker: Helen Ling (London, United Kingdom)

Cognitive Dysfunction and Movement Disorders in Adult-Onset Leukoencephalopathies
Speaker: Takeshi Ikeuchi (Niigata, Japan)

Sponsored Session
12:00 - 13:30
Room "Castor 3"

SS3, Corporate Session 2

Plenary Session
13:30 - 15:00
Plenary

B3, The Treatment of Parkinson Disease: 200 Years Later

Learning Objectives
- To describe the current pharmacotherapy of Parkinson disease
- To understand the current surgical treatments for Parkinson disease
- To explain the principal non-pharmacological therapies for Parkinson disease

Chair: Beom Jeon (Seoul, Korea, Republic of)
Chair: Sheng-Di Chen (Shanghai, China)

Pharmacological Advances in Parkinson Disease Treatment
Speaker: Fabrizio Stocchi (Rome, Italy)

The Current State of Functional Neurosurgical Therapy in Parkinson Disease
Speaker: Elena Moro (Grenoble, France)

The Most Promising Non-Pharmacological Therapies for Parkinson Disease
Speaker: Bastiaan Bloem (Nijmegen, Netherlands)

Skills Workshop
15:30 - 17:00
Room "Pollux 1"

H1, Skills Workshop 1: Deep Brain Stimulation Surgery

Learning Objectives
- To define the optimal patient characteristics for deep brain stimulation
- To learn tips for deep brain stimulation programming
- To identify and manage complications of deep brain stimulation

Chair: Joachim Krauss (Hannover, Germany)
Chair: Thomas Bruecke (Vienna, Austria)

The Ideal Patient for Deep Brain Stimulation Surgery
Speaker: Elena Moro (Grenoble, France)

Pearls and Pitfalls in Deep Brain Stimulation Programming
Speaker: Joohi Jimenez-Shahed (Houston, United States)
Clinical Practice Session
15:30 - 17:00
Room "Pollux 2"

G4, Therapy for Parkinson Disease Part I

Learning Objectives
- To describe current medications for the treatment of Parkinson disease
- To explain the management of medication-induced motor side effects in the treatment of Parkinson disease
- To explain the management of medication-induced cognitive and behavioral side effects in the treatment of Parkinson disease

Chair: Andrzej Friedman (Warsaw, Poland)

Current Conventional Pharmacotherapeutical Interventions
Speaker: Rajesh Pahwa (Kansas City, KS, United States)
15:30 - 16:00

Addressing Motor Pharmacotherapeutical Complications in Parkinson Disease
Speaker: Thomas Mueller (Berlin, Germany)
16:00 - 16:30

Addressing the Cognitive and Behavioral Pharmacotherapeutical Complications of Parkinson Disease
Speaker: Stuart Isaacson (Boca Raton, FL, United States)
16:30 - 17:00

Pho Hot Topic Session
15:30 - 17:00
Room "Castor 1"

C1, Focusing on Gut Microbiota

Learning Objectives
- To explain gastrointestinal dysfunction and pathology in Parkinson disease
- To identify the major findings of gastrointestinal biopsy studies in Parkinson disease
- To describe future challenges in understanding the gut microbiota in Parkinson disease

Chair: Ivan Bodis-Wollner (Brooklyn, NY, United States)
Chair: Pramod Pal (Bengaluru, Karnataka, India)

Past: Historical Overview and the Pathology of Gastrointestinal Dysfunctions in Parkinson Disease
Speaker: Ailton Melo (Salvador, Brazil)
15:30 - 16:00

Present: What We Have Learned from Gastrointestinal Biopsy Studies in Parkinson Disease?
Speaker: Kathleen Shannon (Madison, WI, United States)
16:00 - 16:30

Future Perspectives: The Enteric Glia, Small Intestinal Bacterial Overgrowth, and Microbiota in Parkinson Disease
Speaker: Roberto Cilia (Milan, Italy)
16:30 - 17:00
Point-Counterpoint Interactive Session
15:30 - 17:00
Room "Castor 2"

D1, Are SPECT Scans Useful for the Diagnosis of Parkinson Disease and Other Parkinsonian Disorders?

Learning Objectives
- To appreciate the pros and cons of using SPECT scans for diagnosis of Parkinson and related diseases

Chair: Mark Lew (Los Angeles, CA, United States)

**Yes: SPECT Scans are Useful for the Diagnosis of Parkinson Disease and Other Parkinsonian Disorders!**
Speaker: Angelo Antonini (Venice, Padova, Italy)
15:30 - 16:00

**No: SPECT Scans are NOT Useful for the Diagnosis of Parkinson Disease and Other Parkinsonian Disorders!**
Speaker: Jon Stoessl (Vancouver, Canada)
16:00 - 16:30

**Debate**
16:30 - 16:45

**Question and Answer**
16:45 - 17:00

Timeline Parallel Session
15:30 - 17:00
Room "Castor 3"

F9, Are We Ready for Digital Technology in the Assessment and Management of Parkinson Disease?

Learning Objectives
- To summarize the benefits and drawbacks of traditional outcome measures in Parkinson disease
- To understand the uses of digital technology as clinical trial outcome measures
- To explain the benefits of wearable sensors in treating Parkinson disease

Chair: Roongroj Bhidayasiri (Bangkok, Thailand)

**Historical Perspective: The Pros and Cons of Conventional Outcome Measures in Parkinson Disease**
Speaker: Shen-Yang Lim (Kuala Lumpur, Malaysia)
15:30 - 16:00

**The Present: The Invasion of Digital Technology in Parkinson Clinical Trials**
Speaker: Alberto Espay (Cincinnati, OH, United States)
16:00 - 16:30

**The Future: How Wearable Sensors Can Transform Parkinson Management**
Speaker: Erwin Van Wegen (Amsterdam, Netherlands)
16:30 - 17:00

Oral Poster Session
15:30 - 17:00
Poster Exhibition

OP-3, Oral Poster Presentation - Session III Parkinson 1: Etiology/ Epidemiology/ Pathophysiology

Chair: Irena Rektorova (Brno, Czech Republic)
Chair: Ioannis Isaias (Wuerzburg, Germany)

**Objective versus subjective assessments of freezing of gait: An observational study of patients with Parkinson's disease and related disorders in Singapore**
Speaker: Shuang Yu Nicole Chia (Singapore, Singapore)
Oral health of Parkinson's disease patients, a case-control study  
Speaker: Cees de Baat (Oegstgeest, Netherlands)

Rare GCH1 heterozygous variants contributing to Parkinson's disease  
Speaker: Jifeng Guo (Changsha, China)

Rapid eye movement behavior disorder in drug-naïve patients with Parkinson's disease  
Speaker: Hui Liu (Chengdu, China)

Patients and their caregivers' burdens for Parkinson's disease in Korea  
Speaker: Jong Sam Baik (Seoul, Korea, Republic of)

Greater motor progression in patients with Parkinson disease who carry Park 16 variant  
Speaker: Xiao Deng (Nanning, China)

The association between early treatment with amantadine and delayed onset of levodopa-induced dyskinesia in patients with Parkinson's disease  
Speaker: Tsai Ling Wu (Taipei, Taiwan)

Clinical features and life quality in normosmic Parkinson's Disease  
Speaker: ShiShuang Cui (Shanghai, China)

Glucocerebrosidase gene mutation in Parkinson's disease  
Speaker: Mabel Macas (Manila, Philippines)

Impaired finger dexterity and nigrostriatal dopamine loss in Parkinson's disease  
Speaker: Jinho Kim (Gwanju, Korea, Republic of)

Comorbid conditions associated with Parkinson's disease: a population-based study from the Nebraska Parkinson’s Disease Registry  
Speaker: John Bertoni (Omaha, United States)

Reduced arm swing during gait in patients with Parkinson disease: objective motion analysis study  
Speaker: Young Min Park (Seoul, Korea, Republic of)

Body composition, sarcopenia and frailty in a multi-ethnic Asian cohort with Parkinson's disease  
Speaker: Ai Huey Tan (Kuala Lumpur, Malaysia)

Diagnostic value of striatal-prefrontal projection estimated by cerebral blood flow and dopamine transporter SPECT in Parkinsonian syndromes  
Speaker: Yoshikazu Nakano (Chiba, Japan)

Pain in Parkinson disease: a local single-center correlational study of ambulatory parkinson disease patients  
Speaker: Michelle Ann C. Sy (Manila, Philippines)

Meeting the Professor  
15:30 - 17:00  
Meet the Professor Lounge (Exhibition)

J2, Meet the Professor 2  
Professor: Stanley Fahn (New York, NY, United States)

Meetings  
17:15 - 18:45  
Plenary

IAPRD Annual General Meeting  
Chair: Daniel Truong (Fountain Valley, CA, United States)
Tuesday, 14 November 2017

Clinical Practice Session
08:30 - 10:00

G5, Therapy for Parkinson Disease Part II

Learning Objectives
-To describe non-pharmacologic treatments for Parkinson disease
-To understand the role of medications that continuously stimulate the dopaminergic system in Parkinson disease
-To explain the use of surgical interventions such as deep brain stimulation in Parkinson disease

Chair: Yih-Ru Wu (Taoyuan, Taiwan)
Chair: van Tuan Le (Ho Chi Minh City, Viet Nam)

08:30 - 09:00
Non-Pharmacotherapeutical Interventions in Parkinson Disease
Speaker: Jawad Bajwa (Riyadh, Saudi Arabia)

09:00 - 09:30
The Role of Continuous Dopaminergic Stimulation in Parkinson Disease
Speaker: Angelo Antonini (Venice, Padova, Italy)

09:30 - 10:00
Surgical Interventions in Parkinson Disease
Speaker: Joachim Krauss (Hannover, Germany)

Global Video Session
08:30 - 10:00

E1, Phenomenology of Movement Disorders

Learning Objectives
-To recognize the clinical signs of hypokinesias
-To recognize the clinical signs of hyperkinesias
-To recognize the clinical signs of less common movement disorders

Chair: Raymond Rosales (Quezon City, Philippines)

08:30 - 09:00
The Most Relevant Hypokinetic Disorders
Speaker: Ramon Rodriguez (Gainesville, FL, United States)

09:00 - 09:30
Hyperkinetic Disorders Everyone Needs to Recognize
Speaker: Shen-Yang Lim (Kuala Lumpur, Malaysia)

09:30 - 10:00
The Most Unusual and Fascinating Movement Disorders
Speaker: Roongroj Bhidayasiri (Bangkok, Thailand)

Pho Hot Topic Session
08:30 - 10:00

C4, Focusing on the Multidisciplinary Approach to Parkinson Disease and Other Movement Disorders

Learning Objectives
-To learn about the importance of rehabilitation and exercise in Parkinson disease
-To describe treatment of sexual dysfunction in movement disorders
-To understand the importance of nutrition in Parkinson disease

Chair: Diego Torres-Russotto (Omaha, NE, United States)
Chair: Minh Le (Ho Chi Minh City, Viet Nam)
Run, Pedal, Stretch: The Inevitable Role of Rehabilitation and Exercise in Parkinson Disease
Speaker: Jay Alberts (Cleveland, OH, United States)

Bedtime Stories: Addressing Sexual Dysfunction in Movement Disorders
Speaker: Carlos Singer (Miami, FL, United States)

The Most Relevant Nutritional Issues in Parkinson Disease
Speaker: Emanuele Cereda (Pavia, Italy)

Point-Counterpoint Interactive Session
08:30 - 10:00
Room "Castor 2"

D4, Deep Brain Stimulation in Early Parkinson Disease: Is it Ready for Prime Time?
Learning Objectives
- To understand the pros and cons of deep brain stimulation for early Parkinson disease

Chair: Jean-Philippe Azulay (Marseille, France)
Chair: Tai Tran (Ho Chi Minh, Viet Nam)

Deep Brain Stimulation in Early Parkinson Disease: It is Ready for Prime Time!
Speaker: Michele Tagliati (Los Angeles, CA, United States)

Deep Brain Stimulation in Early Parkinson Disease: It is NOT Ready for Prime Time!
Speaker: Beom Jeon (Seoul, Korea, Republic of)

Debate
09:45 - 10:00

Timeline Parallel Session
08:30 - 10:00
Room "Castor 3"

F1, Dystonia: Past, Present and Future
Learning Objectives
- To understand the history of dystonias
- To learn the pathophysiology of dystonia and current treatment options
- To outline recent dystonia findings and potential future treatments

Chair: Hyder Jinnah (Atlanta, GA, United States)

The Colorful History of Dystonia
Speaker: Dirk Dressler (Hannover, Germany)

The Pathophysiology of Dystonia and Its Current Treatment
Speaker: Hyder Jinnah (Atlanta, GA, United States)

The Most Promising Advances and Future Treatments
Speaker: Marie Vidailhet (Paris, France)
OP-4, Oral Poster Presentation - Session IV Parkinson 2: Treatment

Chair: Joohi Jimenez-Shahed (Houston, United States)
Chair: Wassilios Meissner (Bordeaux, France)

Efficacy of rasagiline and selegiline in Parkinson's disease: a head-to-head 3-year retrospective case-control study
Speaker: Gianni Pezzoli (Pavia, Italy)

Physical activity and its impact on non-motor aspects of Parkinson's disease - The early Parkinson's disease Longitudinal Singapore (PALS) study
Speaker: Yong Ern Samuel Ng (Singapore, Singapore)

Beneficial effect of laughter yoga and clapping exercise in Parkinson's disease patients in south Delhi metro population
Speaker: Vinod Sharma (New Delhi, India)

Efficacy of sublingual apomorphine film (APL-130277) for the treatment of OFF episodes in subjects with Parkinson's disease: preliminary results from the Phase-3 study dose-titration phase
Speaker: Alberto Espay (Cincinnati, OH, United States)

Depression in Parkinson's disease: relation with the level of "given up" activities
Speaker: Sarah Bogard (Montréal, Canada)

Long-term efficacy of inhaled levodopa in Parkinson's disease subjects with motor fluctuations: interim results of a phase 3 study
Speaker: Charles Oh (Ardsley, United States)

Pooled analysis of phase 3 studies of ADS-5102 for levodopa-induced dyskinesia: A detailed review of MDS-UPDRS, part IV (motor complications)
Speaker: Caroline Tanner (San Francisco, CA, United States)

The influence of smell and taste disturbances on the nutritional status in Parkinson disease
Speaker: Magdalena Koszewicz (Wroclaw, Poland)

Safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06649751, an oral Dopamine D1/D5 agonist, in Parkinson's disease: A single ascending dose study
Speaker: David Gray (Cambridge, United States)

Safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral Dopamine D1/D5 agonist PF-06649751 in Parkinson's disease: A multiple ascending dose study
Speaker: David Gray (Cambridge, United States)

Therapeutic effect of non-invasive vagus nerve stimulation in gait disturbance and freezing in Parkinson's disease patients
Speaker: Banashree Mondal (Kolkata, India)

The availability of anti-Parkinsonian drugs in Thailand and associated factors
Speaker: Karn Sakdisornchai (Bangkok, Thailand)

Value of intraoperative neurophysiological monitoring for clinical outcome of deep brain stimulation of subthalamic nucleus in Parkinson's disease
Speaker: Anna Gamaleya (Moscow, Russian Federation)

A naturalistic observation on 20 consecutive patients under LCIG at the “Tor Vergata” University; enforced counseling and alternative route of LD delivery for avoiding discontinuation?
Speaker: Alessandro Stefani (Rome, Italy)
B4, Revisiting the Classical Motor Disorders Impacting the Globe

Learning Objectives
- To describe parkinsonism, its variation around the globe, and treatment evolution
- To describe dystonia, its variation around the globe, and treatment evolution
- To describe tremor, its variation around the globe, and treatment evolution

Chair: Rupam Borgohain (Hyderabad, India)
Chair: Roongroj Bhidayasiri (Bangkok, Thailand)

Parkinsonism: Then and Now 10:30 - 11:00
Speaker: Fabrizio Stocchi (Rome, Italy)

Dystonia: Then and Now 11:00 - 11:30
Speaker: Cynthia Comella (Chicago, IL, United States)

Tremor: Then and Now 11:30 - 12:00
Speaker: Elan Louis (New Haven, CT, United States)

SS5, Corporate Session 3

Sponsored Session
12:00 - 13:30
Room "Castor 1"

SS4, Corporate Session 4

Sponsored Session
12:00 - 13:30
Room "Castor 3"

B5, When Lightning Strikes Twice: Finding the Balance Between Motor Symptoms and Behavior in 3 Complex Movement Disorders

Learning Objectives
- To understand the pathology, clinical characteristics, and treatment of Huntington disease
- To understand the pathology, clinical characteristics, and treatment of Tourette Syndrome
- To understand the clinical characteristics and treatment of psychogenic movement disorders

Chair: Cynthia Comella (Chicago, IL, United States)
Chair: Daniel Truong (Fountain Valley, CA, United States)

Huntington Disease: What We Have Learned Since the Gene was Discovered 13:30 - 14:00
Speaker: Joseph Jankovic (Houston, United States)

The Colorful Spectrum of Tourette Syndrome and Its Medical, Surgical and Behavioral Therapies 14:00 - 14:30
Speaker: Jan Roth (Praha, Czech Republic)

The Most Promising Advances in our Understanding and Treatment of Psychogenic Movement Disorders 14:30 - 15:00
Speaker: Mark Hallett (Bethesda, MD, United States)
Vietnamese Session
15:30 - 17:00
Room "Pollux 2"

Vietnamese Movement Disorder Session
Chair: Minh Le (Ho Chi Minh City, Viet Nam)
Chair: Huu Cong Nguyen (Ho Chi Minh City, Viet Nam)

15:30 - 15:42
Report on the Activity of a Movement Disorder Unit at the Teaching Hospital University Medical Center
Speaker: Ngoc Tai Tran (Ho Chi Minh City, Viet Nam)

15:42 - 15:54
Botulinum Neurotoxin A for the Treatment of Cervical Dystonia: A 5-Year Case Series Study
Speaker: Ngoc Tai Tran (Ho Chi Minh City, Viet Nam)

15:54 - 16:06
Cognitive Impairment and Dementia in Vietnamese Parkinsonian Patients: A Prevalence Study
Speaker: Cong Thang Tran (Ho Chi Minh City, Viet Nam)

16:06 - 16:18
Depression in Parkinson Disease: An Initial Study with the Beck Depression Inventory
Speaker: Thanh Binh Nguyen (Hanoi, Viet Nam)

16:18 - 16:30
Deep Brain Stimulation for Parkinson Disease and other Movement Disorders in Vietnamese Patients: Initial Results
Speaker: Anh Tuan Pham (Ho Chi Minh City, Viet Nam)

16:30 - 16:42
Acanthocytosis in Vietnam
Speaker: Trang Vo Nguyen Ngoc (Ho Chi Minh City, Viet Nam)

16:42 - 16:54
Mitochondrial-Membrane Protein-Associated Neurodegeneration (MPAN): A Case Report
Speaker: Thi Huyen Thuong Dang (Ho Chi Minh City, Viet Nam)

Timeline Parallel Session
15:30 - 17:00
Room "Castor 1"

F6, The Painful Truth About Pain in Movement Disorders

Learning Objectives
-To describe the clinical methods for evaluating pain in movement disorders
-To outline the assessment and treatment of pain in Parkinson disease
-To outline the assessment and treatment of pain in hyperkinetic disorders

Chair: Maja Relja (Zagreb, Croatia)

15:30 - 16:00
The Clinical Assessment of Pain in Movement Disorders
Speaker: Heinz Reichmann (Dresden, Germany)

16:00 - 16:30
The Approach to Pain in Parkinson Disease
Speaker: Raymond Rosales (Quezon City, Philippines)

16:30 - 17:00
When Movement Disorders Hurt: Addressing Pain in Hyperkinetic Disorders
Speaker: Maja Relja (Zagreb, Croatia)
E4, Parade of Movement Disorders From Around the Globe

Learning Objectives
- To understand common movement disorders in Asia
- To understand common movement disorders in South America
- To understand common movement disorders in Africa

Chair: Hubert Fernandez (Cleveland, OH, United States)

Movement Disorders in Asia
Speaker: Thien T. Lim (George Town, Malaysia) 15:30 - 16:00

Movement Disorders in South America
Speaker: Oscar Bernal-Pacheco (Bogotá, Colombia) 16:00 - 16:30

Movement Disorders in Africa
Speaker: Oluwadamilola Ojo (Lagos, Nigeria) 16:30 - 17:00

Timeline Parallel Session

F4, Past, Present and Future of Huntington Disease Care

Learning Objectives
- To describe the clinical methods for evaluating pain in movement disorders
- To outline the assessment and treatment of pain in Parkinson disease
- To outline the assessment and treatment of pain in hyperkinetic disorders

Chair: Kathleen Shannon (Madison, WI, United States)
Chair: Gulnora Rakhimbaeva (Taskent, Uzbekistan)

Huntington Disease Care: From the Past to the Present
Speaker: Tiago Mestre (Ottawa, Canada) 15:30 - 16:00

The Current and Emerging Trends of Huntington Disease Care at Multidisciplinary Centers
Speaker: Kathleen Shannon (Madison, WI, United States) 16:00 - 16:30

Is There a Role for Deep Brain Stimulation Surgery in Huntington Disease?
Speaker: Jean-Philippe Azulay (Marseille, France) 16:30 - 17:00

Oral Poster Session

OP-5, Oral Poster Presentation - Session V The TOP 15 Presentations - Nominee for Best Poster

Chair: Christian Baumann (Zurich, Switzerland)
Chair: Elena Moro (Grenoble, France)

Evaluation of various movement disorders in patients of genetically proven Spino Cerebellar Ataxia: A study from a tertiary care center in Northern India
Speaker: Divya Madathiparambil Radhakrishnan (Delhi, India)

Impaired freeze response in psychogenic (functional) movement disorder patients during exposure to stress
Speaker: Selma Aybek (Bern, Switzerland)
MicroRNA-4639 is a regulator of DJ-1 expression and a potential diagnostic marker for early Parkinson’s disease
Speaker: Yimeng Chen (Shanghai, China)

Chronic Mucuna pruriens in Parkinson’s disease: a non-inferiority, randomised, crossover, phase-2b trial
Speaker: Roberto Cilia (Milan, Italy)

Visual spatial dysfunction and retinal nerve fiber layer thickness in patients with Parkinson Disease
Speaker: Pei Chiek Teh (Wilayah Persekutuan Kuala Lumpur, Malaysia)

Turn cranio-caudal signature assessment from inertial systems for mobility deficit identification in Parkinson’s disease patients
Speaker: Karina Lebel (Sherbrooke, Canada)

Long term results of the VANTAGE study: A prospective multicenter trial evaluating deep brain stimulation with a multiple source, constant current system in Parkinson’s disease
Speaker: Thomas Bruecke (Vienna, Austria)

Results from a phase 1b multiple ascending-dose study of PRX002/RG7935, an Anti-alpha-synuclein monoclonal antibody, in patients with Parkinson’s disease
Speaker: Daniel K. Ness (South San Francisco, United States)

An electrical muscle stimulation therapy for intractable tremor in Parkinson’s disease: a randomized sham-controlled trial of a tremor’s glove device
Speaker: Onanong Jitkritsadakul (Bangkok, Thailand)

Zonisamide improves Parkinsonism in Dementia with Lewy Bodies (DLB): A randomized double-blind placebo-controlled Phase 3 study
Speaker: Kazuko Hasegawa (Sagamihara, Japan)

Cooperative synthesis of dopamine by striatal non-dopaminergic neurons as a mechanism of neuroplasticity at parkinsonism
Speaker: Aleksandr Kim (Moscow, Russian Federation)

Effects of once-daily valbenazine on Tardive Dyskinesia by body region
Speaker: Scott Siegert (San Diego, United States)

Safety and efficacy of DaxibotulinumtoxinA for injection (RT002) in cervical dystonia (CD): Results of a phase 2, dose escalating study
Speaker: Daniel Truong (Fountain Valley, CA, United States)

Video amplification as a sensitive screening tool for orthostatic tremor
Speaker: Diego Torres-Russotto (Omaha, NE, United States)

Meeting the Professor
15:30 - 17:00
Meet the Professor Lounge (Exhibition)

J3, Meet the Professor 3

Professor: Mark Hallett (Bethesda, MD, United States)
**Skills Workshop**

**17:30 - 19:00**

**Plenary**

**H2, Skills Workshop 2: Botulinum Toxin Injections**

**Learning Objectives**
- To learn injection techniques for the treatment of blepharospasm, hemifacial spasm, and jaw dystonia with botulinum toxin
- To learn injection techniques for the treatment of cervical dystonia with botulinum toxin
- To learn injection techniques for the treatment of limb dystonia and spasticity with botulinum toxin

Chair: Daniel Truong (Fountain Valley, CA, United States)
Chair: Tai Tran (Ho Chi Minh, Viet Nam)

**17:30 - 17:55**

**Blepharospasm, Hemifacial Spasm and Jaw Dystonia**

**Speaker:** Mark S. LeDoux (Memphis, United States)

**17:55 - 18:20**

**Cervical Dystonia**

**Speaker:** Raymond Rosales (Quezon City, Philippines)

**18:20 - 18:45**

**Limb Dystonia and Spasticity**

**Speaker:** Ramon Rodriguez (Gainesville, FL, United States)

**18:45 - 19:00**

**Live Demonstrations**

---

**Clinical Practice Session**

**17:30 - 19:00**

**Room "Pollux 1"**

**G8, Dystonia and Sleep Related Movement Disorders**

**Learning Objectives**
- To describe the pathophysiology and classification of dystonias
- To outline the signs, symptoms, and treatment of dystonias
- To summarize sleep-related movement disorders and their treatment

Chair: Dirk Dressler (Hannover, Germany)
Chair: Trang Vo Nguyen Ngoc (Ho Chi Minh City, Viet Nam)

**17:30 - 18:00**

**Dystonia: Pathophysiology/Classification**

**Speaker:** Joohi Jimenez-Shahed (Houston, United States)

**18:00 - 18:30**

**Dystonia: Clinical Aspects/Treatment**

**Speaker:** Dirk Dressler (Hannover, Germany)

**18:30 - 19:00**

**Sleep-Related Movement Disorders**

**Speaker:** Christian Baumann (Zurich, Switzerland)

---

**Clinical Practice Session**

**17:30 - 19:00**

**Room "Pollux 2"**

**G9, Parkinson-Plus Syndromes**

**Learning Objectives**
- To summarize clinical aspects and treatment of multiple system atrophy
- To summarize clinical aspects and treatment of progressive supranuclear palsy
- To summarize clinical aspects and treatment of corticobasal degeneration and corticobasal syndrome

Chair: Heinz Reichmann (Dresden, Germany)

**17:30 - 18:00**

**Multiple System Atrophy**

**Speaker:** Paola Sandroni (New York, United States)
Progressive Supranuclear Palsy
Speaker: Alfonso Fasano (Toronto, Canada)

Corticobasal Degeneration and Corticobasal Syndrome
Speaker: Diego Torres-Russotto (Omaha, NE, United States)

Timeline Parallel Session
17:30 - 19:00
Room "Castor 1"

**F3, Essential Tremor: Reflecting on the Past, and Leaping into the Future**

Learning Objectives
- To characterize the signs and diagnosis of essential tremor and its evolution over time
- To analyze the contribution of genetic and environmental factors to essential tremor
- To describe current and potential future treatments for essential tremor

Chair: Ioannis Isaias (Wuerzburg, Germany)
Chair: Saltanat Kamenova (Almaty, Kazakhstan)

**The Evolving Definition of Essential Tremor**
Speaker: Elan Louis (New Haven, CT, United States)
17:30 - 18:00

**The Etiology of Essential Tremor: Genes versus Environment**
Speaker: Rick Helmich (Nijmegen, Netherlands)
18:00 - 18:30

**Treating Essential Tremor: The Current and Most Promising Therapies**
Speaker: Rajesh Pahwa (Kansas City, KS, United States)
18:30 - 19:00

Global Video Session
17:30 - 19:00
Room "Castor 2"

**E2, The Pearls and Pitfalls of Psychogenic Movement Disorders**

Learning Objectives
- To recognize and diagnose psychogenic movement disorders
- To recognize organic movement disorders that appear psychogenic
- To recognize psychogenic movement disorders that appear organic

Chair: Pramod Pal (Bengaluru, Karnataka, India)

**The Diagnosis and Clinical Manifestations of Psychogenic Movement Disorders**
Speaker: Stanley Fahn (New York, NY, United States)
17:30 - 18:00

**Organic Movement Disorders that Appear Psychogenic**
Speaker: Xin Xin Yu (Cleveland, OH, United States)
18:00 - 18:30

**Psychogenic Movement Disorders that Appear Organic**
Speaker: Alberto Espay (Cincinnati, OH, United States)
18:30 - 19:00
Timeline Parallel Session
17:30 - 19:00
Room "Castor 3"

**F5, Autoimmune Movement Disorders: Current Understanding and Future Directions**

**Learning Objectives**
- To understand immune-mediated autoimmune movement disorders and their treatment
- To understand paraneoplastic autoimmune movement disorders and their treatment
- To understand non-paraneoplastic autoimmune movement disorders and their treatment

Chair: Rukmini Mridula (Panjagutta, Hyderabad, India)

- **Infection-Mediated Autoimmune Movement Disorders**
  - Speaker: Alessandro DiRocco (New York, United States)
  - 17:30 - 18:00

- **Paraneoplastic Autoimmune Movement Disorders**
  - Speaker: Thien T. Lim (George Town, Malaysia)
  - 18:00 - 18:30

- **Non-paraneoplastic Autoimmune Movement Disorders**
  - Speaker: Joseph Jankovic (Houston, United States)
  - 18:30 - 19:00

Oral Poster Session
17:30 - 19:00
Poster Exhibition

**OP-6, Oral Poster Presentation - Session VI Parkinsonian Syndromes / Behavior and Cognition**

Chair: Yih-Ru Wu (Taoyuan, Taiwan)
Chair: Tiago Mestre (Ottawa, Canada)

- **Cognitive impairment in Parkinson’s disease: Correlation with Apolipoprotein E genetic polymorphism and plasma a-synuclein**
  - Speaker: Nor Aslina Samat (Cheras, Malaysia)

- **LRRK2 GTPase domain variants in Dementia**
  - Speaker: Xiao Jin Zhang (Singapore, Singapore)

- **Clinical and cardiac autonomic profile of Parkinsonian and cerebellar phenotypes of probable multiple system atrophy**
  - Speaker: Malligurki Raghurama Rukmani (Bangalore, India)

- **Novel POLG mutation in a patient with early-onset parkinsonism, progressive external ophthalmoplegia and optic atrophy**
  - Speaker: Lin Ma (Beijing, China)

- **Impulse control disorder frequency in different parkinsonism syndromes**
  - Speaker: Muhittin Akbostanci (Ankara, Turkey)

- **Color vision impairment in Dementia with Lewy Bodies and prodromal Lewy bodies, a simple distinguishing feature from Alzheimer’s Dementia and prodromal Alzheimer’s disease**
  - Speaker: Babak Tousi (Cleveland, United States)

- **Impact of frontal lobe function and behavioral changes on quality of life in patients with multiple system atrophy**
  - Speaker: Lingyu Zhang (Chengdu, China)

- **Analysis of GWAS-linked variants in multiple system atrophy**
  - Speaker: Xiaojing Gu (Chengdu, China)

- **Association analysis of SNP rs11868035 in SREBF1 with Parkinson’s disease, amyotrophic lateral sclerosis and multiple system atrophy in Chinese population**
  - Speaker: Xiaoqin Yuan (Chengdu, China)
Diagnostic markers in the pathogenesis of parkinsonism syndrome development in chronic brain ischemia
Speaker: Khakim Khajibakiev (Tashkent, Uzbekistan)

Autonomic function tests in Parkinson’s disease and Multiple System Atrophy
Speaker: Trang Vo Nguyen Ngoc (Ho Chi Minh, Viet Nam)

Comparison of gait parameters between drug-naive patients with multiple system atrophy with predominant Parkinsonism and Parkinson’s disease
Speaker: Boo Suk Na (Seoul, Korea, Republic of)

Interrelationships between survival, sex and blood pressure in patients with multiple system atrophy
Speaker: Chava Peretz (Tel Aviv, Israel)

CSF biological markers of neurodegeneration in patients with Lewy Body Disease (LBD) and Progressive Supranuclear Palsy (PSP)
Speaker: Monika Frolova (Olomouc, Czech Republic)
Clinical Practice Session
08:30 - 10:00
Room "Pollux 1"

G6, Genetics in Parkinson Disease and Movement Disorders

Learning Objectives
- To outline the genes associated with Parkinson and related diseases
- To describe the relationship between genotype and phenotype in parkinsonism
- To describe mitochondrial genetics in Parkinson disease and other movement disorders

Chair: Zbigniew Wszolek (Jacksonville, FL, United States)

Genetics of Parkinson Disease and Parkinson Disease-Like Genotypes
Speaker: Vincenzo Bonifati (Rotterdam, Netherlands) 08:30 - 09:00

Genetics of Parkinson Disease and Parkinson Disease-Like Phenotypes
Speaker: Robin Wu (Taipei, Taiwan) 09:00 - 09:30

Mitochondrial Genetics in Parkinson Disease and Other Movement Disorders
Speaker: Sheng-Di Chen (Shanghai, China) 09:30 - 10:00

Clinical Practice Session
08:30 - 10:00
Room "Pollux 2"

G10, Other Hyperkinetic Disorders

Learning Objectives
- To summarize clinical aspects and treatment of myoclonus
- To summarize clinical aspects and treatment of chorea and tics
- To summarize clinical aspects and treatment of cerebellar syndromes

Chair: William Ondo (Houston, United States)

Myoclonus
Speaker: Jose Martin Rabey (Tel Aviv, Israel) 08:30 - 09:00

Chorea and Tics
Speaker: Karen Frei (Loma Linda, CA, United States) 09:00 - 09:30

Cerebellar Syndromes
Speaker: Shinsuke Fujioka (Fukuoka, Japan) 09:30 - 10:00

Timeline Parallel Session
08:30 - 10:00
Room "Castor 1"

F7, Pathology of Parkinsonism and Related Disorders

Learning Objectives
- To describe alpha synuclein pathology in parkinsonism
- To explain the role of autophagy and the ubiquitin proteasome system in cells and their potential contribution to parkinsonian pathology
- To understand inflammation and other immune mechanisms in parkinsonian pathology

Chair: Peter Riederer (Wuerzburg, Germany)

Unfolding the Mystery of Alpha Synuclein
Speaker: Dennis Dickson (Jacksonville, FL, United States) 08:30 - 09:00
Breaking Down Autophagy and UPS  
Speaker: Young Jun Oh (Seoul, Korea, Republic of)  
09:00 - 09:30

Immune and Inflammatory Mechanisms in Parkinsonism  
Speaker: Ryuji Kaji (Tokushima, Japan)  
09:30 - 10:00

Global Video Session  
08:30 - 10:00  
Room "Castor 2"

**E3, Challenging Hyperkinetic Movement Disorders: Spotlight on Ataxia, Chorea and Myoclonus**

**Learning Objectives**
- To recognize the signs of ataxia
- To distinguish choreas associated with different disorders
- To recognize and treat myoclonus

Chair: Jawad Bajwa (Riyadh, Saudi Arabia)

- **Simplifying the Complicated World of Ataxia**  
  Speaker: Achal Srivastava (New Delhi, India)  
  08:30 - 09:00

- **The Colorful Spectrum of Chorea: From Garden Variety to Rare Disorders**  
  Speaker: Jan Roth (Praha, Czech Republic)  
  09:00 - 09:30

- **Understanding Myoclonus: Presentation, Work Up and Treatment**  
  Speaker: Mark Hallett (Bethesda, MD, United States)  
  09:30 - 10:00

Timeline Parallel Session  
08:30 - 10:00  
Room "Castor 3"

**F10, When It's Not Just Parkinson Disease: Associated Comorbidities and Other Movement Disorders**

**Learning Objectives**
- To describe the signs and management of sleep disorders and restless leg syndrome in Parkinson disease
- To explain the overlapping characteristics of essential tremor and Parkinson disease
- To understand the major comorbidities in Parkinson disease

Chair: Ivan Bodis-Wollner (Brooklyn, NY, United States)

- **Sleep Disorders and Restless Legs Syndrome in Parkinson Disease**  
  Speaker: Christian Baumann (Zurich, Switzerland)  
  08:30 - 09:00

- **The Overlap Between Essential Tremor and Parkinson Disease**  
  Speaker: Alfonso Fasano (Toronto, Canada)  
  09:00 - 09:30

- **Comorbidities in Parkinson Disease**  
  Speaker: Caroline Tanner (San Francisco, CA, United States)  
  09:30 - 10:00

Oral Poster Session  
08:30 - 10:00  
Poster Exhibition

**OP-7, Oral Poster Presentation - Session VII Hyperkinetic Movement Disorders**

Chair: Dirk Dressler (Hannover, Germany)  
Chair: Paola Sandroni (New York, United States)
A clinical cross-sectional study of Huntington's Disease patients from China
Speaker: Wanglin Liu (Chengdu, China)

Shaky and unsteady: Dynamic posturography in essential tremor
Speaker: Shweta Prasad (Bangalore, India)

Ocular motor disorders among X-linked Dystonia Parkinsonism (XDP) patients
Speaker: Mabel Macas (Manila, Philippines)

Cervical dystonia: clinical features of 50 cases in Vietnam
Speaker: Tai Tran (Ho Chi Minh, Viet Nam)

Evaluation of the relationship between cigarette smoking with risk of essential tremor in Singapore population
Speaker: Fiona Setiawan (Singapore, Singapore)

Differential gene expression analysis reveals pathway based functional association of dysregulated genes in Friedreich's ataxia
Speaker: Himanshu Narayan Singh (Delhi, India)

Efficacy and safety of Valbenazine (NBI-98854) in subjects with tardive dyskinesia: Results of a long-term study (KINECT 3 extension)
Speaker: Scott Siegert (San Diego, United States)

Stop signal reaction time in Cervical Dystonia and Parkinson's patients
Speaker: Akash Roy (Kolkata, India)

Writer's Cramp: Brainstem connection revisited
Speaker: Supriyo Choudhury (Kolkata, India)

Tremor in spinocerebellar ataxia type12 (SCA-12) mimics essential tremor (ET)
Speaker: Manpreet Kaur Narang (New Delhi, India)

Volumetric magnetic resonance imaging differences in essential tremor compared to Parkinson's disease
Speaker: Giulia Franco (Nashville, United States)

Neuromodulation of NBIA-related dystonia
Speaker: Tomasz Kmiec (Warszawa, Poland)

Preliminary evidence of functional compensation in premanifest Huntington's disease using a novel visuospatial working memory task
Speaker: Maria Soloveva (Melbourne, Australia)

Differences in botulinum toxin treated and non-treated cervical dystonia patients in somatosensory task-related functional imaging response
Speaker: Martin Nevrly (Olomouc, Czech Republic)

Plenary Session
10:30 - 11:45

I1, Movement Disorder Developments 2016-2017: Best articles published in Parkinsonism and Related Disorders
Chair: Vincenzo Bonifati (Rotterdam, Netherlands)
Chair: Ronald Pfeiffer (Portland, OR, United States)
Chair: Zbigniew Wszolek (Jacksonville, FL, United States)

Status of PRD
Speaker: Ronald Pfeiffer (Portland, OR, United States)
Speaker: Zbigniew Wszolek (Jacksonville, FL, United States)

Best Articles Published in Parkinsonism and Related Disorders
Speaker: Eng-King Tan (Singapore, Singapore)
Speaker: Andreas Puschmann (Lund, Sweden)
Melvin Yahr Awards
Chair: Daniel Truong (Fountain Valley, CA, United States)
Chair: Alessandro DiRocco (New York, United States)

- **Longitudinal effects of cognitive rehabilitation in Parkinson’s disease: a cognitive, clinical and neuroimaging study**
  Speaker: María Díez-Cirarda (Bilbao, Spain)  
  11:45 - 11:55

- **Volumetric magnetic resonance imaging differences in essential tremor compared to Parkinson’s disease**
  Speaker: Giulia Franco (Nashville, United States)  
  11:55 - 12:05

- **MicroRNA-4639 is a regulator of DJ-1 expression and a potential diagnostic marker for early Parkinson’s disease**
  Speaker: Yimeng Chen (Shanghai, China)  
  12:05 - 12:15